Shilpa Gupta, MBBS, is an Assistant Professor in the Division of Hematology, Oncology and Transplantation and the lead for the Phase 1 Interdisciplinary Solid Tumor Program at the Masonic Cancer Center, University of Minnesota, Minneapolis, USA. Prior to joining University of Minnesota in July 2015, Dr. Gupta was faculty in Genitourinary Oncology and Experimental Therapeutics at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida for over 4 years. She obtained her medical degree at the Lady Hardinge Medical College in New Delhi, India, after which she did a fellowship through the Royal College of General Practitioners, in the UK. She pursued a master’s in health informatics at the University of Minnesota and went on to do residency in internal medicine at the University of Connecticut Health Center and Hematology-Oncology Fellowship at Georgetown University and Thomas Jefferson University. She then completed a genitourinary translational research fellowship at Thomas Jefferson University. She has served as a panel member on NCCN committees for kidney and testicular cancers and is a member of several national and international professional organizations, including ASCO, AUA, SUO, AACR, ESMO, and EORTC.
Dr. Gupta’s research interests are to develop novel targeted therapies and immunotherapies in genitourinary cancers, including prostate, bladder, testicular, kidney and penile cancers. Dr. Gupta is the principal investigator of several early and late phase clinical trials exploring novel immunotherapy agents and immunotherapy and targeted therapy combinations. In her efforts to offer a precision medicine and a personalized approach to improve outcomes in genitourinary cancers, she has developed several investigator-initiated trials, including brentuximab and bevacizumab in CD30+ germ cell tumors and bevacizumab in CD30+ germ cell tumors, enzalutamide and gemcitabine-cisplatin in metastatic bladder cancer, and several other novel and VEGF-TKI and immunotherapy combination trials. She has also worked with computation biology professionals to develop personalized biomarker-based treatment algorithms based on individual patient’s cancer biology. Dr. Gupta is passionate about her research and has published her research across a variety of peer-reviewed journals and book chapters.